Nanotechnologies in Bioscience: Targeted Therapeutics & Drug Development – Webinar, 10 May 2013
Nanotechnology is an emerging technology with enormous potential in the bioscience industry, including biotechnology, medicine, medical technology, disease treatment and human healthcare. This online webinar is aimed at introducing the potential for nano-enabled innovations in the field of Biosciences leading into a more focused discussion on the topic of targeted therapeutics and drug development.
Date & Time
- Friday 10 May 2013, 12pm – 1pm EDT
- Dr. Toby Gill, Nanotechnology Professional, UK
- Dr. Jeff Hrkach, Senior Vice President of Technology, Research and Development, BIND Therapeutics
Nanotechnologis in Bioscience
Dr. Toby Gill will provide a brief overview of some of the current developments taking place around the applications of nanotechnologies in the field of Biosciences. This general introduction is aimed at those interested in learning more about the emerging applications of nanotechnologies in biosciences.
Targeted Therapeutics & Drug Development
Dr. Jeff Hrkach will present different approaches to targeted therapeutics such as molecularly targeted drug molecules, nano medicines and antibody-drug conjugates. His talk will include a case study about Accurins™, a new class of highly selective targeted therapeutics that achieve high and prolonged concentrations at the site of disease, creating optimal therapeutic indices. Accurins™ are precisely engineered to have long circulation half-lives, finely tuned pharmacokinetics and surface-bound targeting ligands that bind selectively to cell-surface receptors on diseased cells.
BIND Therapeutics is developing Accurins™ targeted therapeutics, primarily focused on oncology, using proprietary and partner drug molecules including cytotoxics and molecularly-targeted kinase inhibitors.
Register to attend at – http://xtalks.com/nanotechnology-drug-therapeutics.ashx